ClinicalTrials.gg
RecruitingNCT05755386APPARENTUpdated Jul 13, 2026

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

A Phase 3 interventional study of Placebo and iptacopan in IC-MPGN, sponsored by Novartis Pharmaceuticals. Recruiting at 131 sites in 23 countries. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Proteinuria by Novartis — 7 open to participants now, 7 under way, 4 of them phase 3. Proteinuria · Novartis.

Started
2023
the only one that year
Phase 3
5 of 12
4 open now
Registered
7th of 12
by date

Among the 12 studies in Proteinuria by Novartis, this one is the only one that started in 2023, is one of 5 in phase 3, and was the 7th registered.

Proteinuria

329 studies on the registry are indexed under Proteinuria; 44 are open to participants now.

Browse Proteinuria studies →

Open to participants now

7 of the 12 studies in Proteinuria by Novartis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 32 Proteinuria studies recruiting now, 12 (38%) set no upper age limit and 16 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Proteinuria by Novartis, or all of them as a file.
02

Study summary

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

Read the detailed description

The purpose of this Phase III study is to evaluate the efficacy and safety of iptacopan compared to placebo (both administered in combination with standard of care) in participants (adults and adolescents aged 12-17 years) with idiopathic IC-MPGN. The study aims to demonstrate a reduction in proteinuria and improvement in estimated glomerular filtration rate (eGFR) in participants treated with iptacopan compared to placebo. Change in patient-reported fatigue will also be evaluated. Alternative complement pathway (AP) dysregulation is believed to underlie the clinical manifestations and progression of IC-MPGN. Upon completion of study treatment, participants will have the option to discontinue iptacopan treatment and enter a 30 day safety follow-up or continue iptacopan treatment by transitioning to an open label extension study (CLNP023B12001B; NCT03955445) and continue iptacopan treatment.

03

Conditions studied

  • IC-MPGN

Browse trials for

Keywords

  • LNP023
  • IC-MPGN
  • iptacopan
  • UPCR
  • eGFR
  • proteinuria
04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients including adults (aged at least 18 years to ≤ 60 years) and adolescents (12 -17 years in non-EU countries at screening and 16-17 years in EU countries at screening).
  • Diagnosis of idiopathic IC-MPGN as confirmed by kidney within 12 months prior to screening in adults and within 3 years of screening in adolescents (a biopsy report, review and confirmation by the Investigator is required). If such a biopsy is not available in an adult participant, this must be obtained at screening (performed and assessed locally for adults only).
  • Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of renin angiotensin system inhibitors (RASi), e.g an ACEi or ARB for at least 90 days (or as according to local guidelines). The doses of other drugs administered to reduce proteinuria and control the disease including mycophenolic acids (MPAs - mycophenolate mofetil or mycophenolate sodium), , SGLT2 inhibitors and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization
  • UPCR ≥ 1.0 g/g (≥ 113 mg/mmol) sampled from the first morning void urine sample at Day -75 and Day -15
  • Estimated (using the chronic kidney disease [CKD]-EPI formula for adult participants and modified Schwartz formula for adolescents aged 12 to 17 years) or measured GFR ≥ 30 ml/min/1.73m2 at screening and Day -15.
  • Mandatory vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection prior to the start of study treatment. If the participant has not been previously vaccinated, or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of study treatment. If the study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated in accordance with local standard of care.
  • If not previously vaccinated, or if a booster is required, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration.

Exclusion criteria

Exclusion Criteria:

  • Participants who have undergone cell or solid organ transplantation, including kidney transplantation.
  • Participants diagnosed with secondary IC-MPGN including but not limited to any of the following conditions:
  • Deposition of antigen-antibody immune complexes as a result of any chronic infections, including

    • virus (HCV) including HCV-associated mixed cryoglobulinemia, virus (HBV);
    • Bacterial-endocarditis, infected ventriculo-atrial shunt, visceral abscesses, leprosy, meningococcal meningitis; chronic bacterial infections
    • Protozoa/other infections- malaria, schistosomiasis, mycoplasma, leishmaniasis, filariasis, histroplasmosis

Renal deposition of immune complexes as a result of a systemic disease:

  • Systemic lupus erythematosus (SLE)
  • Sjögren syndrome
  • Rheumatoid arthritis
  • Mixed connective tissue disease Deposition of monoclonal immunoglobulins because of a monoclonal gammopathy due to plasma cell or B cell disorders. Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care.

Fibrillary glomerulonephritis

  • Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the within 3 months with kidney findings of glomerular crescent formation seen in at least 50% of glomeruli on the most recent biopsy.
  • Kidney biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%.
  • Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration or the presence of fever ≥ 38°C (100.4°F) within 7 days prior to study treatment administration.
  • A history of recurrent invasive infections caused by encapsulated organisms, e.g., Neisseria meningitidis and Streptococcus pneumoniae.
  • The use of inhibitors of complement factors (e.g., Factor B, Factor D, complement 3 (C3) inhibitors, anti-Complement 5 (C5) antibodies, C5a receptor antagonists) within 3 months or 5 half-lives prior to the Screening visit.
  • The use of (except MPAs), cyclophosphamide or systemic at a dose >7.5 mg/day (or equivalent for a similar corticosteroid medication) within 90 days of study drug administration.
  • The use of MPAs is not permitted within 90 days prior to randomization in India, as per the local health authority requirement.
  • Acute post-infectious glomerulonephritis at screening, based upon the opinion of the investigator.
  • (BMI) >38 kg/m2 at screening and randomization. Body weight \<35 kg at screening and randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    iptacopan 200mg b.i.d

    iptacopan 200mg b.i.d

    Drug: iptacopan

  • Placebo comparator
    Placebo to iptacopan 200mg b.i.d.

    Placebo to iptacopan 200mg b.i.d.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

  • iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

06

What researchers measure

Primary outcomes

  1. Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection) at 6 months.

    To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 6 months.

    Time frame: 6 months (double-blind)

  2. Log-transformed ratio to baseline in UPCR at the 18-month visit (each study treatment arm)

    To evaluate the effect of iptacopan on proteinuria at 18 months.

    Time frame: 18 months

  3. Log-transformed ratio to 12-month visit in UPCR at the 18-month visit in the placebo arm.

    To evaluate the effect of iptacopan on proteinuria at 18 months.

    Time frame: 18 months

Secondary outcomes

  1. Change from baseline in eGFR

    To demonstrate the superiority of iptacopan vs. placebo in improving estimated glomerular filtration rate (eGFR).

    Time frame: 12 months and 18 months

  2. Change in eGFR from the 12-month visit to the 18- month visit of the placebo arm

    To evaluate the effect at 18 months of iptacopan in improving eGFR

    Time frame: 18 months

  3. Proportion of patients achieved a composite renal endpoint

    To demonstrate the superiority of iptacopan vs. placebo in the proportion of participant who achieved a composite renal endpoint at 6 and 12 months (each study arm).

    Time frame: 6 and 12 months

  4. Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score.

    To demonstrate the superiority of iptacopan compared to placebo in improvement of patient-reported fatigue at 12 months (each study arm).

    Time frame: 12 months

  5. Number of participants with abnormal vital signs, ECGs and safety laboratory measurements as well as study drug discontinuation due to an AE

    To evaluate the safety and tolerability of iptacopan compared to placebo, number of participants with abnormal vital signs (msDBP/msSBP/heart rate), ECGs, safety laboratory measurements and study drug discontinuation due to an AE will be collected. msDBP: mean sitting diastolic blood pressure msSBP: mean sitting systolic blood pressure

    Time frame: up to 18 months

  6. Number of participants with clinically significant changes in heart rate, blood pressure, echocardiography parameters in adolescent patients

    To evaluate the effect of iptacopan compared to placebo, number of participants with clinically significant changes in heart rate, blood pressure (msDBP/ msSBP), echocardiography parameters in adolescent patients will be collected

    Time frame: up to 18 months

  7. Annualized total eGFR slope estimated over 12 months.

    To demonstrate the superiority of iptacopan vs. placebo in stabilizing eGFR

    Time frame: 12 months

  8. Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection) at 12 months.

    To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 12 months of treatment.

    Time frame: 12 months

  9. Proportion of participants who achieved the composite renal endpoint at 18 months

    To evaluate the effect of iptacopan on proteinuria at 18 months

    Time frame: 18 months

07

Study locations

125 of 131 sites recruiting
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
    Recruiting
  • Univ Cali Irvine ALS Neuromuscular
    Orange, California 92868, United States
    Recruiting
  • UCSF
    San Francisco, California 94115, United States
    Recruiting
  • Olive View UCLA Medical Center
    Sylmar, California 91342, United States
    Recruiting
  • Childrens Hospital Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Nicklaus Childrens Hospital
    Miami, Florida 33155, United States
    Recruiting
  • Emory University School of Medicine-Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Boston Univ School of Medicine
    Boston, Massachusetts 02118, United States
    Recruiting
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Karen Omlung · Contactseve0024@umn.edu · +1 612 262 2750
    • Nattawat Klomjit · Principal investigator
  • Washington University in St Louis
    St Louis, Missouri 63110, United States
    Recruiting
    • Michelle Bloom · Contactmbloom@wustl.edu · +1 314 362 5298
    • Tingting Li · Principal investigator
  • University of New Mexico
    Albuquerque, New Mexico 87131-0001, United States
    Recruiting
    • Susan L Tigert · ContactSTigert@salud.unm.edu · +1 505 272 9992
    • Namita Singh · Principal investigator
  • Col Uni Med Center New York Presby
    New York, New York 10032, United States
    Recruiting
  • University Of Cincinnati
    Cincinnati, Ohio 45267, United States
    Recruiting
  • OHSU Dept of Nephrology
    Portland, Oregon 97239, United States
    Recruiting
    • Madison Stanaway · Contactstanaway@ohsu.edu · +1 503 494 4233
    • Rupali Avasare · Principal investigator
  • Univ of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • MUSC Health Lancaster Med Ctr
    Lancaster, South Carolina 29720, United States
    Recruiting
  • UT Southwestern Medical Center
    Dallas, Texas 75235, United States
    Recruiting
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
    Recruiting
    • Romeo Parada · Contactrparada@prolato.org · +1 832 338 9118
    • Sreedhar Mandayam · Principal investigator
  • Baylor Scott and White Research
    Temple, Texas 76502, United States
    Recruiting
  • University of Utah
    Salt Lake City, Utah 84113, United States
    Recruiting
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
    Recruiting
    • Alana Quackenbush · Contactakquackenbus@wisc.edu · +1 608 265 6020
    • Sharon Bartosh · Principal investigator
  • Novartis Investigative Site
    CABA, Buenos Aires C1425AGC, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, Buenos Aires C1425EFD, Argentina
    Recruiting
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5000, Argentina
    Recruiting
  • Novartis Investigative Site
    Buenos Aires, W3400ABH, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
    Recruiting
  • Novartis Investigative Site
    Santa Fe, S3000EPV, Argentina
    Recruiting
  • Novartis Investigative Site
    Fortaleza, Ceará 60430 370, Brazil
    Recruiting
  • Novartis Investigative Site
    Brasília, Federal District 71635-580, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
    Recruiting
  • Novartis Investigative Site
    Recife, Pernambuco 50740-900, Brazil
    Recruiting
  • Novartis Investigative Site
    Niterói, Rio de Janeiro 24020 096, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Rio de Janeiro, Rio de Janeiro 22211-230, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Natal, Rio Grande do Norte 59012 300, Brazil
    Recruiting
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
    Recruiting
  • Novartis Investigative Site
    Botucatu, São Paulo 18618-970, Brazil
    Recruiting
  • Novartis Investigative Site
    Santo André, São Paulo 09090-790, Brazil
    Recruiting
  • Novartis Investigative Site
    Sao Jose Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 04038-002, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 05403 000, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    São Paulo, São Paulo 05403-000, Brazil
    Recruiting
  • Novartis Investigative Site
    Salvador, 40323-010, Brazil
    Recruiting
  • Novartis Investigative Site
    Etobicoke, Ontario M9W 6V1, Canada
    Recruiting
  • Novartis Investigative Site
    London, Ontario N6A 5W9, Canada
    Recruiting
  • Novartis Investigative Site
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H2X 1R9, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H3T 1C5, Canada
    Recruiting
  • Novartis Investigative Site
    Prague, 128 08, Czechia
    Recruiting
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
    Recruiting
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
    Recruiting
  • Novartis Investigative Site
    Marseille, 13005, France
    Recruiting
  • Novartis Investigative Site
    Montpellier, 34295, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75015, France
    Recruiting
  • Novartis Investigative Site
    Rennes, 35033, France
    Recruiting
  • Novartis Investigative Site
    Toulouse, 31054, France
    Recruiting
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
    Recruiting
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
    Recruiting
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
    Recruiting
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 13353, Germany
    Recruiting
  • Novartis Investigative Site
    Essen, 45147, Germany
    Recruiting
  • Novartis Investigative Site
    Hamburg, 20246, Germany
    Recruiting
  • Novartis Investigative Site
    Hanover, 30625, Germany
    Recruiting
  • Novartis Investigative Site
    Mainz, 55131, Germany
    Recruiting
  • Novartis Investigative Site
    Ulm, 89081, Germany
    Recruiting
  • Novartis Investigative Site
    Athens, 115 27, Greece
    Recruiting
  • Novartis Investigative Site
    Chaïdári, 124 62, Greece
    Recruiting
  • Novartis Investigative Site
    Heraklion Crete., 715 00, Greece
    Recruiting
  • Novartis Investigative Site
    Ioannina, 455 00, Greece
    Recruiting
  • Novartis Investigative Site
    Pátrai, 265 04, Greece
    Recruiting
  • Novartis Investigative Site
    Thessaloniki, 54636, Greece
    Recruiting
  • Novartis Investigative Site
    Thessaloniki, 570 10, Greece
    Recruiting
  • Novartis Investigative Site
    Bangalore, Karnataka 560004, India
    Recruiting
  • Novartis Investigative Site
    Nagpur, Maharashtra 440015, India
    Recruiting
  • Novartis Investigative Site
    Pune, Maharashtra 411011, India
    Recruiting
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
    Recruiting
  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
    Recruiting
  • Novartis Investigative Site
    Haifa, 3109601, Israel
    Recruiting
  • Novartis Investigative Site
    Jerusalem, 9103102, Israel
    Recruiting
  • Novartis Investigative Site
    Petah Tikva, 4920235, Israel
    Recruiting
  • Novartis Investigative Site
    Bari, BA 70124, Italy
    Recruiting
  • Novartis Investigative Site
    Ranica, BG 24020, Italy
    Recruiting
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20122, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00165, Italy
    Recruiting
  • Novartis Investigative Site
    Torino, TO 10126, Italy
    Recruiting
  • Novartis Investigative Site
    Naples, 80131, Italy
    Recruiting
  • Novartis Investigative Site
    Toyoake, Aichi-ken 4701192, Japan
    Recruiting
  • Novartis Investigative Site
    Fuchū, Tokyo 1838561, Japan
    Recruiting
  • Novartis Investigative Site
    Hachiōji, Tokyo 193-0998, Japan
    Recruiting
  • Novartis Investigative Site
    Okayama, 7008558, Japan
    Recruiting
  • Novartis Investigative Site
    Osaka, 558-8558, Japan
    Recruiting
  • Novartis Investigative Site
    Groningen, 9713 GZ, Netherlands
    Recruiting
  • Novartis Investigative Site
    Poznan, Greater Poland Voivodeship 60-355, Poland
    Recruiting
  • Novartis Investigative Site
    Bialystok, 15-540, Poland
    Recruiting
  • Novartis Investigative Site
    Krakow, 30-688, Poland
    Recruiting
  • Novartis Investigative Site
    Olsztyn, 10-561, Poland
    Recruiting
  • Novartis Investigative Site
    Warsaw, 02-006, Poland
    Recruiting
  • Novartis Investigative Site
    Warsaw, 02-097, Poland
    Recruiting

Showing the first 100 of 131 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2028, 60 months after the start.

Of 20 phase 3 interventional studies under Proteinuria, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 78. This study's planned 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 6, 2023
StartActual
Oct 2, 2023
Primary completionEst.
Oct 27, 2028
CompletionEst.
May 31, 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05755386
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Oct 2, 2023
Primary completion
Oct 27, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion